comparemela.com
Home
Live Updates
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3 : comparemela.com
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
Announced Agreement With Nimbus Therapeutics in December to Acquire a Potential Best-in-Class TYK2 Inhibitor, and with HUTCHMED in January to In-license Highly Selective, Oral Tyrosine Kinase... | February 2, 2023
Related Keywords
China ,
Japan ,
United States ,
Canada ,
Hong Kong ,
Philadelphia ,
Pennsylvania ,
Macau ,
,
International Financial Reporting Standards ,
European Commission ,
Arrowhead Pharmaceuticals Inc ,
Exchange Commission ,
China National Medical Products Administration ,
Nimbus Therapeutics ,
Takeda Pharmaceutical Company Limited ,
Constant Exchange Rate ,
Costa Saroukos ,
Launch Products ,
Free Cash Flow ,
Derived Therapies ,
Emerging Markets ,
Major Depressive Disorder ,
With Phase ,
Biologics License ,
National Medical Products Administration ,
Arrowhead Pharmaceuticals ,
Cash Flow ,
Rare Genetics ,
Plasma Derived Therapies ,
Annual Report ,
Score Revenue ,
Core Operating Profit ,
Core Net Profit ,
Net Debt ,
Free Cash ,
Takeda Pharmaceutical Company Limited Stock Exchange ,
News ,
Information ,
Press Release ,
Nnounced ,
Agreement ,
Ith ,
Cnimbus ,
Herapeutics ,
N ,
December ,
O ,
Cquire ,
Potential ,
Tyk2 ,
End ,
Hutchmed ,
January ,
Ighly ,
Mural ,
Yrosine 4502 Jp3463000004 ,
comparemela.com © 2020. All Rights Reserved.